EyeBrain, a Paris, France-based startup developing brain function markers for neurological and psychiatric diseases, has raised €3.3m in second funding.
EyeBrain intends to use the capital to recruit a sales force, expand its network of distributors, and provide marketing support for commercializing its products in new countries (especially in Europe). In addition, the company plans to continue its research and development programs, developing and clinically testing new medical devices that will serve as markers of brain function in neurological and psychiatric diseases.
Founded in 2008 and led by chairman and CEO Serge Kinkingnehun, EyeBrain is developing brain function markers for neurological and psychiatric diseases utilizing devices based on eye motricity. Its EyeBrain Tracker is already being used in hospitals and doctors’ surgeries in France and in several European countries.